Press releases

22 Nov 2022

UCB Submits Response to FDA Complete Response Letter for Bimekizumab

14 Nov 2022

UCB announces U.S. FDA acceptance of new drug application and EMA MAA validation for zilucoplan for the treatment of generalized myasthenia gravis in adult patients

10 Nov 2022

Bimekizumab Demonstrated Sustained Clinical Responses to Week 52 in Phase 3 Studies in Psoriatic Arthritis, Non-Radiographic Axial Spondyloarthritis and Ankylosing Spondylitis

8 Nov 2022

UCB Reinforces Commitment to Rheumatology with 15 Abstracts including New Late-Breaking Data at ACR Convergence 2022

13 Oct 2022

UCB announces positive preliminary results for major brivaracetam (Briviact[®]) study in Asia

27 Sep 2022

FINTEPLA[®▼] (fenfluramine) Approved in Japan for the Treatment of Seizures Associated with Dravet Syndrome

Press releases

Press releases

Search Press releases

UCB Submits Response to FDA Complete Response Letter for Bimekizumab

UCB announces U.S. FDA acceptance of new drug application and EMA MAA validation for zilucoplan for the treatment of generalized myasthenia gravis in adult patients

Bimekizumab Demonstrated Sustained Clinical Responses to Week 52 in Phase 3 Studies in Psoriatic Arthritis, Non-Radiographic Axial Spondyloarthritis and Ankylosing Spondylitis

UCB Reinforces Commitment to Rheumatology with 15 Abstracts including New Late-Breaking Data at ACR Convergence 2022

UCB announces positive preliminary results for major brivaracetam (Briviact[®]) study in Asia

FINTEPLA[®▼] (fenfluramine) Approved in Japan for the Treatment of Seizures Associated with Dravet Syndrome

Choose a Country

Hypothesize That! Discover our new science podcast, where science meets conjecture and curiosity

Publications - A dedicated space where we share a collection of our scientific peer-reviewed...

Pipeline - Check out our clinical development pipeline spanning several therapy areas

At UCB, we imagine an HS-free world. And we’re taking steps to make it a reality. Download our...

WoCBA - Closing the gaps in research in the care of women of childbearing age with chronic diseases

Clinical studies – Click to find out more on our clinical studies

Integrated Annual Report 2025 - Direct access to our latest annual report

UCB Community Health Fund enters a new phase

UCBCares® - Discover what UCBCares® is about and the services they offer

BIMZELX[®]▼(bimekizumab) superior to SKYRIZI[®] (risankizumab) in BE BOLD: first head-to-head study...

Strong Execution Fueling Sustained Company Growth

KYGEVVI[®] (doxecitine and doxribtimine) recommended for approval in the European Union as treatment...

Strong Execution Fueling Sustained Company Growth

Innovation and Execution Power UCB’s Success

Download center – Click here to view a collection of useful documents

Press releases

Search Press releases

UCB Submits Response to FDA Complete Response Letter for Bimekizumab

UCB announces U.S. FDA acceptance of new drug application and EMA MAA validation for zilucoplan for the treatment of generalized myasthenia gravis in adult patients

Bimekizumab Demonstrated Sustained Clinical Responses to Week 52 in Phase 3 Studies in Psoriatic Arthritis, Non-Radiographic Axial Spondyloarthritis and Ankylosing Spondylitis

UCB Reinforces Commitment to Rheumatology with 15 Abstracts including New Late-Breaking Data at ACR Convergence 2022

UCB announces positive preliminary results for major brivaracetam (Briviact[®]) study in Asia

FINTEPLA[®▼] (fenfluramine) Approved in Japan for the Treatment of Seizures Associated with Dravet Syndrome

Choose a Country